Snake Venom and Antivenom Pharmacology

Posted by
  SNAKE VENOM & ANTIVENOM Chemistry, Composition, Mechanisms and Pharmacology Abstract This integrated teaching session for Phase III MBBS students focused on the pharmacology and toxicology of snake venom and the principles of antivenom therapy. The lecture covered the chemistry, composition, mechanisms of action, and pharmacological effects of snake venoms and antivenoms. Rational use of antivenoms, indications, administration protocols, adverse reactions, and supportive management strategies were discussed. The session also highlighted the translational importance of venom-derived compounds in modern drug development. Recent advances in antivenom research, including recombinant human monoclonal antibodies, toxin-specific inhibitors, synthetic antibody technologies, and next-generation broad-spectrum antivenoms, were reviewed. Current discoveries and emerging approaches aimed at improving efficacy, safety, affordability, and accessibility of antivenom therapy were also explor...

Spider Venom-Derived Peptide Exhibits Dual Anti-Inflammatory and Antioxidative Activities in LPS-Stimulated BEAS-2B Cells

Posted by

 


Spider Venom-Derived Peptide Exhibits Dual Anti-Inflammatory and Antioxidative Activities in LPS-Stimulated BEAS-2B Cells

Abstract

Most respiratory diseases are driven by excessive airway inflammation and oxidative stress, yet current therapies often lack durable efficacy or are unsafe. Host-defense peptides, commonly enriched in animal venoms, offer diverse, target-selective scaffolds for new therapeutics. In this study, we aimed to discover a novel bioactive peptide with therapeutic potential on respiratory tract damage by utilizing Nephila clavata venom gland transcriptome. Using in silico analysis and machine learning-based functional prediction, we designed a peptide, NC-CV, expected to have dual anti-inflammatory and antioxidant activities with low cytotoxicity. In experimental validation, NC-CV improved human bronchial epithelial BEAS-2B cell viability under lipopolysaccharide (LPS) exposure while reducing LPS-induced pro-inflammatory cytokine expression and intracellular reactive oxygen species (ROS) generation. Mechanistic studies and molecular docking simulations indicated that NC-CV prevents toll-like receptor 4 signaling activation, suppressing nuclear factor κB and mitogen-activated protein kinase pathways. Moreover, the antioxidant activity of NC-CV was primarily based on direct intracellular ROS scavenging rather than the induction of endogenous antioxidant enzymes. Collectively, these findings demonstrated that the venom-derived peptide NC-CV disrupts the self-reinforcing cycle involving inflammatory signaling and oxidative stress in airway epithelium, highlighting its promise as a therapeutic candidate for respiratory disease.